Navigation Links
Dr. Renu Razdan of Max Neeman International Appointed Vice Chairman, ACRO India
Date:12/5/2013

RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2013 /PRNewswire/ -- The Association of Contract Research Organizations [ACRO] India has appointed Max Neeman's Chief Operating Officer, Dr. Renu Razdan as Vice Chairman. The appointment is effective immediately with key responsibility to create and strengthen the network with regulatory agencies, law makers and scientific community in India.

Max Neeman, a leading Indian provider of clinical research services to the pharmaceutical, biotech and medical device industry for over 10 years, promoted Dr. Razdan to COO in 2009. Prior to joining the company, she worked at Ranbaxy Laboratories Limited as Senior Manager Business Development then Head of Exports, and has also worked with Transasia Biomedicals and HPCL Systems.

Dr. Razdan holds a PhD in Biochemistry from German Cancer Research Centre (DKFZ), Heidelberg, Germany and has been featured as a prominent female achiever in the Life Sciences community; November 2010 issue of 'BioSpectrum India' life science journal.

When asked what she hopes to achieve, Dr. Razdan's response was twofold: 1) to strengthen the channels of communication between industry, regulators and other stakeholders for drug development in India 2) focus on promoting India as a place where good drug development research takes place, despite recent challenges.

About Max Neeman International
'Max Neeman' is a leading Asia-Pacific CRO with India expertise and expanded capabilities into N. America and Europe. Since 2001, the company has provided clinical research services for the successful conduct of drug and device trials in compliance with ICH GCP standards. The company is ISO 9001:2008 certified for monitoring, site management and data management with over >400 employees, 245 active sites in various therapeutic areas and 310 trials awarded. Data Management services alone have touched 60 countries. For more information contact Donald Swankie, Vice President USA:  919.424.3345, donald.swankie@neeman-medical.com or go to www.neeman-medical.com.

About ACRO
ACRO is an independent, non-profit organization with a global perspective. ACRO India, founded and registered in India in Feb 2005, has been formed under the aegis of Confederation of Indian Industry (CII) for bringing all CRO's operating in India on one common platform. With its vision of establishing India as a global sourcing hub for Contract Research, ACRO is used to promote quality research, uphold ethics, share best practices, promote synergies amongst members, to deliberate and act upon common concerns, especially with regards to Indian regulations and industry environment.


'/>"/>
SOURCE Max Neeman International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
5. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
6. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
7. PAREXEL International to Present at J.P. Morgan Healthcare Conference
8. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):